Figure 1.
Overview of the participating COVID-19 cohorts in the CORFU study. The source population included in the individual cohorts is an estimate as of May 2022. The total number of CORFU study participants might not add up to the total source population (n=12 631) due to non-survivors, participants included in multiple cohorts and participants who might not want to participate in the CORFU study. *At the time of manuscript preparation, prospective inclusion is ongoing in five cohorts: Adelante, CAPACITY-COVID, DC&TC, ELVIS and MaastrICCht cohort. CAPACITY-COVID, Cardiac complications in patients with COVID-19 cohorts; CORADS, COVID-19 Reporting and Data System Score; COVAS, Bernhoven Early detection of Vascular damage after COVID-19 cohort; DC&TC cohort, Dutch COVID and Thrombosis Consortium cohort; ELVIS, ZuydErLand COVID-19 regiStry; ICU, Iintensive care unit; MaastrICCht, Maastricht Intensive Care COVID cohort; NSAID, non-steroidal anti-inflammatory drug; POPCOrn, POPulation health impact of the COVID-19 pandemic; PROMS, Patient-Reported Outcome Measures; VTE, venous thromboembolic.
